ArticleBMC cancer2026
Mumio and bladder cancer: unlocking its potential in 3D cell culture.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer remains one of the most prevalent causes of cancer-related mortality worldwide. Mumio, a naturally occurring substance with a long-standing history of use in traditional medicine, has demonstrated therapeutic potential, including anticancer properties. This study aimed to evaluate the effects of a pharmaceutical formulation of Mumio on the growth of normal (SV-HUC-1) and cancerous (T24, 5637) bladder cell lines in 3D culture.
methodsSpheroids were generated using ultra-low attachment 96-well plates. Three concentrations of Mumio (LC₁₀, LC₅₀, LC₉₀), previously determined in 2D culture, were applied. Cells were incubated for 24, 48, and 72 h. Cell viability and caspase activity in 3D culture were assessed via luminescence-based assays. Hematoxylin–eosin (HE) and Ki-67 staining were performed to evaluate spheroid morphology and proliferation. Gene expression analysis was conducted to investigate molecular mechanisms.
resultsMumio exhibited dose-dependent cytotoxicity in 3D culture, with T24 cells showing the highest sensitivity compared to the control and the second bladder cancer cell line (5637) after all incubation times. Concentrations effective in 2D culture were less potent in 3D conditions. Proliferation rates decreased with increasing Mumio concentration and prolonged exposure. Molecular analysis revealed G1 phase cell cycle arrest and reduced DNA synthesis.
conclusionsMumio has potential in supportive bladder cancer treatment; however, its effectiveness, as observed in 2D culture, exhibited diminished efficacy when applied to 3D cultures. Further investigations are necessary, including the use of organoids or animal models, to confirm these properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.